Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Pfizer Inc. (NYSE: PFE) is included among the 13 Best Dividend Stocks Paying Over 6%.

While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

Eli Lilly is riding the wave of a booming weight management market. Eli Lilly's tirzepatide, sold under the brand names ...

Tempus AI stock contract value exceeds $1.1B with 70 pharma deals. Diagnostics revenue up 111%, data segment up 31% in 2025 ...

US stocks extended losses on Wednesday as weakness in tech megacaps outweighed solid economic data and mixed results from ...